{"gene":"ARHGEF1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1998,"finding":"p115 RhoGEF (ARHGEF1) has GTPase-activating protein (GAP) activity specifically toward Gα12 and Gα13, but not Gs, Gi, or Gq subfamily members, mediated through its N-terminal RGS-like domain.","method":"Recombinant protein in vitro GTPase activity assay; fusion protein containing the N-terminus of p115","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — in vitro biochemical reconstitution with recombinant proteins, foundational paper with 727 citations","pmids":["9641915"],"is_preprint":false},{"year":1998,"finding":"Activated Gα13 binds tightly to p115 RhoGEF (ARHGEF1) and directly stimulates its guanine nucleotide exchange activity on RhoA; in contrast, activated Gα12 inhibits this Gα13-mediated stimulation.","method":"Recombinant protein binding assay; in vitro GEF activity assay with purified components","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with purified proteins, 665 citations, replicated by companion paper","pmids":["9641916"],"is_preprint":false},{"year":2001,"finding":"The pleckstrin homology (PH) domain and a linker region between the RGS and DH domains regulate p115 RhoGEF activity: removal of the PH domain reduces in vitro exchange activity, deletion of the C-terminal 150 amino acids enhances in vivo activity over 5-fold, and endogenous p115 RhoGEF translocates from cytosol to membranes upon LPA or sphingosine 1-phosphate stimulation.","method":"Domain deletion mutants; in vitro GEF activity assay; immunoprecipitation of endogenous protein from stimulated cells; subcellular fractionation","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple domain deletion constructs with in vitro and in vivo functional readouts, strong mechanistic detail","pmids":["11384980"],"is_preprint":false},{"year":2000,"finding":"Activated Gα13 induces redistribution of p115 RhoGEF from the cytoplasm to plasma membranes; non-palmitoylated Gα13 mutants co-immunoprecipitate with p115 RhoGEF but fail to cause its translocation to the plasma membrane, indicating palmitoylation of Gα13 is required for p115 RhoGEF membrane recruitment but not the physical interaction.","method":"Co-immunoprecipitation; fluorescence microscopy of transfected cells; palmitoylation-deficient mutants","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP with mutagenesis, clear functional dissociation of binding vs. translocation","pmids":["10747909"],"is_preprint":false},{"year":2003,"finding":"The N-terminal acidic-rich region of p115 RhoGEF, specifically glutamic acids 27 and 29, is required for binding to activated Gα13; however, Gα13-interacting-deficient mutants retain Gα13-dependent plasma membrane recruitment, dissociating binding from translocation.","method":"Cell-based co-immunoprecipitation; site-directed mutagenesis; subcellular localization assay","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 — mutagenesis with functional dissection in cell-based assays, single lab","pmids":["12681510"],"is_preprint":false},{"year":2008,"finding":"Constitutively active Gα12 and Gα13 mutants induce redistribution of p115 RhoGEF (EGFP-tagged) from cytosol to plasma membrane; activation of G12/13-coupled GPCRs causes rapid and reversible translocation of p115 RhoGEF to the plasma membrane.","method":"Live-cell fluorescence imaging of EGFP-tagged p115 RhoGEF; pharmacological GPCR activation and antagonism","journal":"Journal of Cellular Biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct live-cell imaging with constitutively active and pharmacological tools, single lab","pmids":["18320579"],"is_preprint":false},{"year":2009,"finding":"Rho activity is required for Gα13-induced, but not Gα12-induced, plasma membrane translocation of p115 RhoGEF; a constitutively PM-localized mutant of p115 RhoGEF shows greatly enhanced Rho-dependent neurite retraction compared to wild-type, demonstrating that PM localization activates p115 RhoGEF signaling.","method":"Rho inhibition (C3 transferase); PM-localized mutant expression; neurite retraction assay in PC12 cells; RGS domain mutant analysis","journal":"Cellular Signalling","confidence":"Medium","confidence_rationale":"Tier 2 — multiple mutants and functional assay, single lab","pmids":["19249348"],"is_preprint":false},{"year":2009,"finding":"p115 RhoGEF is targeted by microtubules in neighboring epithelial cells to basolateral surfaces during apoptotic cell extrusion; this targeting activates local actin/myosin contraction at the basolateral surface and determines the direction (apical vs. basal) of cell extrusion.","method":"Live-cell imaging; microtubule perturbation; localization of p115 RhoGEF by fluorescence microscopy; inhibition of myosin","journal":"Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 2 — direct imaging with microtubule manipulation, clear functional consequence, 113 citations","pmids":["19720875"],"is_preprint":false},{"year":2010,"finding":"Angiotensin II activates Arhgef1 in arterial smooth muscle cells through JAK2-mediated phosphorylation of Tyr738 of Arhgef1, which in turn activates RhoA signaling; smooth-muscle-specific Arhgef1 inactivation in mice confers resistance to angiotensin II-dependent hypertension.","method":"Kinase inhibition; phosphorylation site mutagenesis (Tyr738); smooth muscle-specific knockout mice; blood pressure measurement; RhoA activity assay","journal":"Nature Medicine","confidence":"High","confidence_rationale":"Tier 1–2 — PTM identification with mutagenesis + genetic KO with defined in vivo phenotype, 204 citations","pmids":["20098430"],"is_preprint":false},{"year":2007,"finding":"Lsc/p115 RhoGEF (ARHGEF1) and LARG are activated downstream of fibronectin adhesion (but not other matrix proteins), and their combined knockdown significantly reduces RhoA activation and formation of stress fibers and focal adhesions; a catalytically inactive Lsc mutant inhibits RhoA activity and cytoskeletal structures on fibronectin.","method":"Affinity pulldown assay for active GEFs; siRNA knockdown; catalytically inactive mutant overexpression; RhoA activity assay; immunofluorescence","journal":"Journal of Cell Science","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (pulldown, siRNA, dominant-negative), 92 citations","pmids":["17971419"],"is_preprint":false},{"year":1999,"finding":"The cytoplasmic leucine-zipper region of HIV-1 gp41 interacts with the C-terminal regulatory domain of p115 RhoGEF and inhibits p115-mediated actin stress fiber formation and SRF activation; loss of this interaction impairs HIV-1 replication in human T cells.","method":"Co-immunoprecipitation; functional assays (stress fiber formation, SRF reporter); mutagenesis of gp41; viral replication assay","journal":"Current Biology","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus functional assays and mutagenesis, single lab","pmids":["10556093"],"is_preprint":false},{"year":2011,"finding":"The linker region connecting the RGS-homology domain and DH domain of p115 RhoGEF acts as an autoinhibitory element (GEF switch); crystal structures of DH/PH alone vs. DH/PH with linker region reveal that the linker disorders the N-terminal extension of the DH domain required for GEF activity.","method":"X-ray crystallography; SAXS; in vitro GEF activity assay of deletion constructs","journal":"Protein Science","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus SAXS and biochemical activity assays, multiple orthogonal methods","pmids":["21064165"],"is_preprint":false},{"year":2012,"finding":"Activation of p115 RhoGEF by Gα13 requires direct association of Gα13 with the DH domain at a site distinct from the RhoA-binding face; the helical domain of Gα13 docks onto the DH domain, and mutation of Trp in the α3b helix of DH reduces Gα13 binding and ablates stimulation; the RH domain facilitates this DH-domain interaction.","method":"SAXS; biochemical binding assays; site-directed mutagenesis of DH domain and Gα13 helical domain; in vitro GEF activity assay","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — structural (SAXS) plus mutagenesis and in vitro activity assays, multiple orthogonal approaches","pmids":["22661716"],"is_preprint":false},{"year":2016,"finding":"Tension on JAM-A activates RhoA via p115 RhoGEF (and GEF-H1) in a pathway dependent on PI3K, Src family kinases, and FAK; phosphorylation of JAM-A at Ser-284 is required for RhoA activation in response to tension.","method":"Pharmacological inhibition; siRNA knockdown; phospho-site mutagenesis; RhoA activity assay; cell stiffness measurement","journal":"Molecular Biology of the Cell","confidence":"Medium","confidence_rationale":"Tier 2 — multiple inhibitors and mutagenesis, functional phenotype, single lab","pmids":["26985018"],"is_preprint":false},{"year":2016,"finding":"FAK/p66Shc complex specifically binds and activates p115 RhoGEF and GEF-H1 in response to mechanical tension on fibronectin, leading to RhoA activation; this complex is required for YAP/TAZ nuclear translocation, proliferation on firm substrates, and anoikis in suspension.","method":"Pulldown/co-IP; domain mapping (PTB domain, FERM domain); siRNA knockdown; RhoA activity assay; YAP/TAZ localization","journal":"Molecular and Cellular Biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding domain mapping and functional knockdown, single lab","pmids":["27573018"],"is_preprint":false},{"year":2017,"finding":"GPCR-induced and hypoxia-induced ROS activate Src-family kinases, which then activate RhoA via ARHGEF1 in pulmonary artery smooth muscle; subcellular translocation of RhoA and ARHGEF1 is triggered by ROS and blocked by antioxidants, PP2, or ARHGEF1 siRNA; ARHGEF1 co-immunoprecipitates with c-Src in a ROS-dependent manner.","method":"Co-immunoprecipitation; siRNA knockdown; live-cell imaging of ARHGEF1 translocation; pharmacological inhibitors; RhoA activity assay","journal":"Free Radical Biology and Medicine","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus siRNA and live imaging, single lab","pmids":["28673614"],"is_preprint":false},{"year":2017,"finding":"MCP1 induces tyrosine phosphorylation of p115 RhoGEF (but not PDZ-RhoGEF or LARG) in vascular smooth muscle cells via CCR2-Gi/o-Fyn signaling, leading to Rac1 (not only RhoA) activation and subsequent HASMC migration and proliferation through a Rac1-NFATc1-cyclin D1-CDK6-PKN1-CDK4-PAK1 axis.","method":"siRNA knockdown; tyrosine phosphorylation analysis; Rac1 activity assay; migration and proliferation assays; in vivo balloon injury model with siRNA","journal":"Journal of Biological Chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo siRNA with signaling pathway analysis, single lab","pmids":["28655771"],"is_preprint":false},{"year":2017,"finding":"TGF-β enhances ARHGEF1 protein expression in airway smooth muscle cells; ARHGEF1 siRNA suppresses TGF-β-enhanced BK-induced RhoA translocation, Rho-kinase activity, and contraction; ARHGEF1 mediates TGF-β effects on airway hyperresponsiveness independently of SrcFK and total RhoA-GTP content.","method":"siRNA knockdown; live-cell imaging of ARHGEF1/RhoA translocation; MYPT1/MLC20 phosphorylation; isolated bronchiole contraction assay","journal":"Journal of Physiology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA with multiple functional readouts including in vitro tissue contraction, single lab","pmids":["29071730"],"is_preprint":false},{"year":2019,"finding":"Loss-of-function mutations in ARHGEF1 in humans result in low RhoA activity and low actin polymerization in T and B lymphocytes; ARHGEF1-deficient lymphocytes fail to restrain AKT phosphorylation downstream of ROCK, and enforced ARHGEF1 expression or RhoA activation corrects impaired actin polymerization and AKT regulation.","method":"Whole-exome sequencing; RhoA activity assay; actin polymerization assay; AKT phosphorylation assay; rescue by ARHGEF1 re-expression or pharmacological RhoA activation","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 — human loss-of-function with multiple molecular readouts and rescue experiments","pmids":["30521495"],"is_preprint":false},{"year":2017,"finding":"Arhgef1 is essential for Ang II-induced integrin activation in leukocytes; deletion of Arhgef1 prevents Ang II-induced leukocyte recruitment to the endothelium; bone marrow reconstitution experiments establish that Arhgef1 in leukocytes (not stromal cells) is causal in atherosclerosis development.","method":"Genetic knockout mice; bone marrow reconstitution; leukocyte adhesion assay; integrin activation assay; atherosclerosis model (high-fat diet, LDLR-/- background)","journal":"Journal of Clinical Investigation","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis via BM reconstitution with clear cellular mechanism, strong evidence","pmids":["29130930"],"is_preprint":false},{"year":2016,"finding":"ARHGEF1 and SOS1 and DOCK2 mediate CXCL12-induced LFA-1 activation in T lymphocytes downstream of JAK kinases; ARHGEF1 is tyrosine phosphorylated upon CXCL12 stimulation in a JAK- and pertussis toxin-sensitive manner, and its knockdown impairs RhoA and Rac1 activation and LFA-1-mediated rapid adhesion.","method":"siRNA knockdown; LFA-1 affinity assay; adhesion assay under flow; RhoA/Rac1 activity assay; tyrosine phosphorylation analysis; JAK and pertussis toxin inhibitors","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays with siRNA and pharmacological tools, single lab","pmids":["27986909"],"is_preprint":false},{"year":2019,"finding":"Arhgef1 deficiency in platelets impairs RhoA-ROCK axis activation, leading to defective aggregation, granule secretion, αIIbβ3 integrin activation, clot retraction, and spreading, as well as prolonged bleeding times and impaired thrombosis in vivo.","method":"Genetic knockout mice; platelet aggregation assay; granule secretion assay; integrin activation assay; clot retraction; carotid artery occlusion model; tail bleeding time","journal":"Journal of the American Heart Association","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo platelet function assays in KO mice, single lab","pmids":["30994039"],"is_preprint":false},{"year":2016,"finding":"Arhgef1 negatively regulates neurite outgrowth by activating RhoA while inhibiting Rac1 and Cdc42; Arhgef1 promotes F-actin polymerization in neurons, likely through inhibiting cofilin activity; pharmacological RhoA blockade rescues excess neurite growth caused by Arhgef1 overexpression.","method":"siRNA knockdown; overexpression in Neuro-2a cells and primary cortical neurons; RhoA/Rac1/Cdc42 activity assays; cofilin phosphorylation analysis; actin staining; neurite length measurement","journal":"FEBS Letters","confidence":"Medium","confidence_rationale":"Tier 2 — gain- and loss-of-function with GTPase activity assays and downstream effector analysis, single lab","pmids":["27489999"],"is_preprint":false},{"year":2022,"finding":"p115 RhoGEF interacts with Gα13 for a significantly shorter duration than LARG or PDZ-RhoGEF, determined by a single amino acid in the rgRGS domain; mutation of this residue increases interaction time with Gα13, enhances agonist sensitivity, and increases GAP activity toward Gα13 in intact cells.","method":"FRET-based single-cell interaction kinetics assay; site-directed mutagenesis; in vitro GAP activity assay","journal":"Communications Biology","confidence":"Medium","confidence_rationale":"Tier 1–2 — FRET kinetics with mutagenesis, in vitro GAP assay, single lab","pmids":["36434027"],"is_preprint":false},{"year":2024,"finding":"Apigenin targets ARHGEF1 to inhibit Cdc42 activity, thereby blocking microvesicle biogenesis from tumor cells and reducing VEGF90K-mediated tumor angiogenesis.","method":"siRNA knockdown; Cdc42 activity assay; microvesicle secretion assay; pharmacological treatment with apigenin; VEGF transport assay","journal":"Cancer Letters","confidence":"Medium","confidence_rationale":"Tier 2 — functional knockdown with mechanistic pathway dissection, single lab","pmids":["38823764"],"is_preprint":false},{"year":2010,"finding":"Arhgef1 regulates α5β1 integrin-mediated matrix metalloproteinase (MMP) expression in macrophages; Arhgef1-deficient macrophages show increased MMP expression and activity when cultured on fibronectin in an α5β1-dependent manner.","method":"Genetic knockout mice; macrophage culture on fibronectin; MMP activity assay; integrin blocking antibodies; in vivo leukocyte transfer","journal":"American Journal of Pathology","confidence":"Medium","confidence_rationale":"Tier 2 — KO macrophages with integrin-specific blocking and in vivo transfer, single lab","pmids":["20093499"],"is_preprint":false}],"current_model":"ARHGEF1 (p115 RhoGEF) is a RGS domain-containing guanine nucleotide exchange factor that directly links Gα12/13 heterotrimeric G protein signaling to RhoA activation: its RGS domain acts as a GAP for Gα12/13 while activated Gα13 docks onto both the RH and DH domains to relieve autoinhibition imposed by a linker region and stimulate RhoA exchange activity; the protein is also tyrosine-phosphorylated (e.g., Tyr738 by JAK2 downstream of angiotensin II, or by Src-family kinases and Fyn downstream of chemokine/ROS signaling) to activate RhoA and Rac1 in vascular smooth muscle, leukocytes, platelets, and neurons, with Gα13-driven plasma membrane translocation constituting an additional activation mechanism; these activities regulate cytoskeletal dynamics, cell migration and adhesion, apoptotic cell extrusion, neurite outgrowth, and vascular tone."},"narrative":{"teleology":[{"year":1998,"claim":"Establishing that p115 RhoGEF is both a GAP for Gα12/13 and the effector through which Gα13 directly stimulates RhoA exchange activity resolved the long-standing question of how G12/13-coupled receptors activate Rho GTPases.","evidence":"In vitro reconstitution with recombinant proteins measuring GTPase acceleration and nucleotide exchange","pmids":["9641915","9641916"],"confidence":"High","gaps":["Structural basis of simultaneous GAP and GEF activities not yet resolved","Relative contributions of Gα12 vs. Gα13 to physiological signaling unclear"]},{"year":2000,"claim":"Demonstration that Gα13 drives plasma membrane translocation of p115 RhoGEF in a palmitoylation-dependent manner established membrane recruitment as a key activation mechanism, separable from the physical Gα13–p115 interaction.","evidence":"Co-immunoprecipitation and fluorescence microscopy with palmitoylation-deficient Gα13 mutants in transfected cells","pmids":["10747909"],"confidence":"High","gaps":["Identity of the membrane-targeting determinant on p115 RhoGEF itself unknown","Whether endogenous receptors use the same translocation mechanism not shown"]},{"year":2001,"claim":"Mapping of intramolecular regulatory elements showed that the PH domain supports catalytic activity while the C-terminal region autoinhibits it, and that endogenous p115 RhoGEF translocates upon GPCR ligand stimulation, linking domain architecture to signal-dependent activation.","evidence":"Domain deletion mutants with in vitro GEF assays; subcellular fractionation of endogenous protein after LPA/S1P stimulation","pmids":["11384980"],"confidence":"High","gaps":["Atomic mechanism of autoinhibition not resolved at this stage","Role of the C-terminal region as a protein–protein interaction platform only partially explored"]},{"year":2007,"claim":"Identification of ARHGEF1 (together with LARG) as fibronectin-specific integrin-activated RhoGEFs placed the protein in the adhesion-to-cytoskeleton signaling axis beyond GPCR pathways.","evidence":"Affinity pulldown for active GEFs, siRNA knockdown, and dominant-negative mutant in cells on fibronectin","pmids":["17971419"],"confidence":"High","gaps":["Direct integrin–ARHGEF1 binding not demonstrated","Upstream kinases linking integrin engagement to ARHGEF1 activation not identified"]},{"year":2009,"claim":"Discovery that neighboring epithelial cells target p115 RhoGEF to the basolateral surface via microtubules during apoptotic extrusion revealed a non-GPCR, cytoskeleton-directed mechanism of spatial activation with direct morphogenetic consequence.","evidence":"Live-cell imaging with microtubule perturbation and myosin inhibition in epithelial monolayers","pmids":["19720875"],"confidence":"High","gaps":["Molecular link between microtubule plus-ends and p115 RhoGEF targeting unknown","Whether this mechanism operates in vivo tumor cell extrusion untested"]},{"year":2010,"claim":"Identification of JAK2-mediated Tyr738 phosphorylation as the angiotensin II–induced activation switch, coupled with the hypertension-resistant phenotype of smooth-muscle-specific Arhgef1 knockout mice, established ARHGEF1 as a central mediator of vascular tone.","evidence":"Phospho-site mutagenesis, kinase inhibition, conditional knockout mice, and blood pressure measurement","pmids":["20098430"],"confidence":"High","gaps":["Whether other tyrosine sites contribute to activation in vascular smooth muscle not resolved","Downstream effectors beyond ROCK not fully mapped in vivo"]},{"year":2011,"claim":"Crystal structures of the DH/PH cassette with and without the linker region revealed that the linker disorders the N-terminal DH extension required for catalysis, defining the structural basis of autoinhibition (the 'GEF switch').","evidence":"X-ray crystallography and SAXS combined with in vitro GEF activity assays of truncation constructs","pmids":["21064165"],"confidence":"High","gaps":["How Gα13 binding relieves this autoinhibition structurally not captured in a single complex structure"]},{"year":2012,"claim":"Mapping the Gα13–DH domain interface to the α3b helix showed that Gα13 contacts a surface distinct from the RhoA-binding face, with the RH domain facilitating this interaction, explaining how Gα13 allosterically stimulates exchange activity.","evidence":"SAXS, site-directed mutagenesis of DH and Gα13 helical domains, and in vitro GEF assays","pmids":["22661716"],"confidence":"High","gaps":["Full atomic-resolution structure of the ternary Gα13–p115–RhoA complex lacking","Whether linker displacement and DH-domain contact are sequential or concerted not determined"]},{"year":2016,"claim":"Parallel studies in T lymphocytes and mechanotransduction showed ARHGEF1 is tyrosine-phosphorylated downstream of JAK/Src-family kinases upon chemokine or mechanical stimulation to activate both RhoA and Rac1, broadening its effector spectrum beyond RhoA alone and linking it to integrin inside-out signaling and YAP/TAZ mechanosensing.","evidence":"siRNA knockdown, LFA-1 affinity/adhesion assays, phosphorylation analysis, RhoA/Rac1 pulldowns, YAP/TAZ localization","pmids":["27986909","27489999","27573018","26985018"],"confidence":"Medium","gaps":["Direct phosphorylation by Src-family kinases at specific residues not mapped","Whether Rac1 activation is direct or via an intermediate pathway unresolved","Relative contribution of ARHGEF1 vs. GEF-H1 in mechanotransduction not quantified"]},{"year":2017,"claim":"In vivo studies using Arhgef1-knockout mice with bone marrow reconstitution demonstrated that leukocyte-intrinsic Arhgef1 is required for angiotensin II–induced integrin activation, endothelial adhesion, and atherosclerosis development, establishing a cell-autonomous immune function.","evidence":"Bone marrow chimera in LDLR−/− mice, leukocyte adhesion assay, integrin activation assay","pmids":["29130930"],"confidence":"High","gaps":["Specific Gα subunit upstream of Arhgef1 in leukocytes not identified","Whether the vascular and immune roles synergize in atherogenesis not dissected"]},{"year":2019,"claim":"Human loss-of-function mutations in ARHGEF1 were shown to cause defective RhoA-dependent actin polymerization and ROCK-mediated AKT restraint in lymphocytes, rescued by ARHGEF1 re-expression, establishing ARHGEF1 deficiency as a cause of primary immunodeficiency.","evidence":"Whole-exome sequencing, RhoA/actin/AKT assays in patient lymphocytes, rescue by ARHGEF1 expression or pharmacological RhoA activation","pmids":["30521495"],"confidence":"High","gaps":["Full clinical spectrum of ARHGEF1 deficiency in additional kindreds not defined","Whether the AKT dysregulation drives lymphomagenesis not tested"]},{"year":2022,"claim":"FRET-based kinetic analysis revealed that p115 RhoGEF has a much shorter interaction time with Gα13 than LARG or PDZ-RhoGEF, determined by a single rgRGS-domain residue, suggesting that differential kinetics tune signaling output among the three RH-RhoGEFs.","evidence":"Single-cell FRET kinetics, site-directed mutagenesis, and in vitro GAP assay","pmids":["36434027"],"confidence":"Medium","gaps":["Physiological consequence of altered interaction kinetics not demonstrated in native tissue","Whether kinetic differences translate to distinct downstream signaling dynamics unknown"]},{"year":null,"claim":"A high-resolution structure of the full-length Gα13–p115 RhoGEF–RhoA ternary complex and the precise mechanism by which tyrosine phosphorylation at Tyr738 allosterically activates GEF activity remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No ternary complex structure available","Structural basis of phospho-Tyr738-mediated activation unknown","In vivo redundancy among RH-RhoGEFs not systematically addressed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,23]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,11,12]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3,5]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,5,6]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,8,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18,19,20]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[21]}],"complexes":[],"partners":["GNA13","GNA12","RHOA","JAK2","SRC","FYN","FAK","LARG"],"other_free_text":[]},"mechanistic_narrative":"ARHGEF1 (p115 RhoGEF) is a Gα12/13-regulated guanine nucleotide exchange factor for RhoA that couples heterotrimeric G protein signaling to cytoskeletal remodeling, cell adhesion, vascular tone, immune cell trafficking, and apoptotic cell extrusion. Its N-terminal RGS domain functions as a GTPase-activating protein selective for Gα12 and Gα13 [PMID:9641915], while activated Gα13 binds the DH domain at a site distinct from the RhoA-binding surface to relieve autoinhibition imposed by an interdomain linker, as revealed by crystallography and SAXS [PMID:21064165, PMID:22661716]; Gα13-driven palmitoylation-dependent translocation to the plasma membrane further potentiates signaling [PMID:10747909, PMID:18320579]. Tyrosine phosphorylation by JAK2 (Tyr738, downstream of angiotensin II) or Src-family kinases activates ARHGEF1-dependent RhoA and Rac1 signaling in vascular smooth muscle, leukocytes, and platelets, and smooth-muscle-specific knockout confers resistance to angiotensin II-induced hypertension [PMID:20098430, PMID:27986909, PMID:29130930]. Loss-of-function mutations in human ARHGEF1 cause impaired RhoA-mediated actin polymerization and dysregulated AKT signaling in lymphocytes, resulting in primary immunodeficiency [PMID:30521495]."},"prefetch_data":{"uniprot":{"accession":"Q92888","full_name":"Rho guanine nucleotide exchange factor 1","aliases":["115 kDa guanine nucleotide exchange factor","p115-RhoGEF","p115RhoGEF","Sub1.5"],"length_aa":912,"mass_kda":102.4,"function":"Seems to play a role in the regulation of RhoA GTPase by guanine nucleotide-binding alpha-12 (GNA12) and alpha-13 (GNA13) subunits (PubMed:9641915, PubMed:9641916). Acts as a GTPase-activating protein (GAP) for GNA12 and GNA13, and as guanine nucleotide exchange factor (GEF) for RhoA GTPase (PubMed:30521495, PubMed:8810315, PubMed:9641915, PubMed:9641916). Activated G alpha 13/GNA13 stimulates the RhoGEF activity through interaction with the RGS-like domain (PubMed:9641916). This GEF activity is inhibited by binding to activated GNA12 (PubMed:9641916). Mediates angiotensin-2-induced RhoA activation (PubMed:20098430). In lymphoid follicles, may trigger activation of GNA13 as part of S1PR2-dependent signaling pathway that leads to inhibition of germinal center (GC) B cell growth and migration outside the GC niche","subcellular_location":"Cytoplasm; Membrane","url":"https://www.uniprot.org/uniprotkb/Q92888/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARHGEF1","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARHGEF1","total_profiled":1310},"omim":[{"mim_id":"618459","title":"IMMUNODEFICIENCY 62; IMD62","url":"https://www.omim.org/entry/618459"},{"mim_id":"616858","title":"COWDEN SYNDROME 7; CWS7","url":"https://www.omim.org/entry/616858"},{"mim_id":"613510","title":"LATE ENDOSOMAL/LYSOSOMAL ADAPTOR, MAPK AND MTOR ACTIVATOR 1; LAMTOR1","url":"https://www.omim.org/entry/613510"},{"mim_id":"610512","title":"SEC23 HOMOLOG B, COAT COMPLEX II COMPONENT; SEC23B","url":"https://www.omim.org/entry/610512"},{"mim_id":"606905","title":"PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE-DEPENDENT RAC EXCHANGER 1; PREX1","url":"https://www.omim.org/entry/606905"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Plasma membrane","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":165.2}],"url":"https://www.proteinatlas.org/search/ARHGEF1"},"hgnc":{"alias_symbol":["P115-RHOGEF","SUB1.5","LBCL2"],"prev_symbol":[]},"alphafold":{"accession":"Q92888","domains":[{"cath_id":"1.10.167.10","chopping":"44-228","consensus_level":"high","plddt":89.5764,"start":44,"end":228},{"cath_id":"1.20.900.10","chopping":"397-615","consensus_level":"high","plddt":95.3774,"start":397,"end":615},{"cath_id":"2.30.29.30","chopping":"633-692_702-760","consensus_level":"high","plddt":93.6402,"start":633,"end":760}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92888","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92888-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92888-F1-predicted_aligned_error_v6.png","plddt_mean":73.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARHGEF1","jax_strain_url":"https://www.jax.org/strain/search?query=ARHGEF1"},"sequence":{"accession":"Q92888","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92888.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92888/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92888"}},"corpus_meta":[{"pmid":"9641915","id":"PMC_9641915","title":"p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9641915","citation_count":727,"is_preprint":false},{"pmid":"9641916","id":"PMC_9641916","title":"Direct stimulation of the guanine nucleotide exchange activity of p115 RhoGEF by Galpha13.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9641916","citation_count":665,"is_preprint":false},{"pmid":"20098430","id":"PMC_20098430","title":"The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure.","date":"2010","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20098430","citation_count":204,"is_preprint":false},{"pmid":"19720875","id":"PMC_19720875","title":"P115 RhoGEF and microtubules decide the direction apoptotic cells extrude from an epithelium.","date":"2009","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19720875","citation_count":113,"is_preprint":false},{"pmid":"17971419","id":"PMC_17971419","title":"A novel role for Lsc/p115 RhoGEF and LARG in regulating RhoA activity downstream of adhesion to fibronectin.","date":"2007","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/17971419","citation_count":92,"is_preprint":false},{"pmid":"10747909","id":"PMC_10747909","title":"Galpha 13 requires palmitoylation for plasma membrane localization, Rho-dependent signaling, and promotion of p115-RhoGEF membrane binding.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10747909","citation_count":73,"is_preprint":false},{"pmid":"11384980","id":"PMC_11384980","title":"Identification of potential mechanisms for regulation of p115 RhoGEF through analysis of endogenous and mutant forms of the exchange factor.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11384980","citation_count":64,"is_preprint":false},{"pmid":"10556093","id":"PMC_10556093","title":"Functional interaction between the cytoplasmic leucine-zipper domain of HIV-1 gp41 and p115-RhoGEF.","date":"1999","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/10556093","citation_count":49,"is_preprint":false},{"pmid":"28673614","id":"PMC_28673614","title":"ROS-dependent activation of RhoA/Rho-kinase in pulmonary artery: Role of Src-family kinases and ARHGEF1.","date":"2017","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28673614","citation_count":44,"is_preprint":false},{"pmid":"30521495","id":"PMC_30521495","title":"Loss of ARHGEF1 causes a human primary antibody deficiency.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/30521495","citation_count":39,"is_preprint":false},{"pmid":"26985018","id":"PMC_26985018","title":"Tension on JAM-A activates RhoA via GEF-H1 and p115 RhoGEF.","date":"2016","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/26985018","citation_count":35,"is_preprint":false},{"pmid":"22661716","id":"PMC_22661716","title":"Activation of p115-RhoGEF requires direct association of Gα13 and the Dbl homology domain.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22661716","citation_count":35,"is_preprint":false},{"pmid":"21064165","id":"PMC_21064165","title":"Modulation of a GEF switch: autoinhibition of the intrinsic guanine nucleotide exchange activity of p115-RhoGEF.","date":"2011","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/21064165","citation_count":31,"is_preprint":false},{"pmid":"18320579","id":"PMC_18320579","title":"Reversible translocation of p115-RhoGEF by G(12/13)-coupled receptors.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18320579","citation_count":29,"is_preprint":false},{"pmid":"28655771","id":"PMC_28655771","title":"p115 RhoGEF activates the Rac1 GTPase signaling cascade in MCP1 chemokine-induced vascular smooth muscle cell migration and proliferation.","date":"2017","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28655771","citation_count":29,"is_preprint":false},{"pmid":"25870189","id":"PMC_25870189","title":"Angiotensin II activates the RhoA exchange factor Arhgef1 in humans.","date":"2015","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/25870189","citation_count":26,"is_preprint":false},{"pmid":"29071730","id":"PMC_29071730","title":"Transforming growth factor-β enhances Rho-kinase activity and contraction in airway smooth muscle via the nucleotide exchange factor ARHGEF1.","date":"2017","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/29071730","citation_count":24,"is_preprint":false},{"pmid":"26911374","id":"PMC_26911374","title":"Cdc42 and Rac1 activity is reduced in human pheochromocytoma and correlates with FARP1 and ARHGEF1 expression.","date":"2016","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/26911374","citation_count":24,"is_preprint":false},{"pmid":"27573018","id":"PMC_27573018","title":"p66Shc Couples Mechanical Signals to RhoA through Focal Adhesion Kinase-Dependent Recruitment of p115-RhoGEF and GEF-H1.","date":"2016","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27573018","citation_count":19,"is_preprint":false},{"pmid":"19249348","id":"PMC_19249348","title":"Differences in Galpha12- and Galpha13-mediated plasma membrane recruitment of p115-RhoGEF.","date":"2009","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/19249348","citation_count":18,"is_preprint":false},{"pmid":"27986909","id":"PMC_27986909","title":"SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27986909","citation_count":17,"is_preprint":false},{"pmid":"27489999","id":"PMC_27489999","title":"Arhgef1 negatively regulates neurite outgrowth through activation of RhoA signaling pathways.","date":"2016","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/27489999","citation_count":17,"is_preprint":false},{"pmid":"29130930","id":"PMC_29130930","title":"Leukocyte RhoA exchange factor Arhgef1 mediates vascular inflammation and atherosclerosis.","date":"2017","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29130930","citation_count":16,"is_preprint":false},{"pmid":"20093499","id":"PMC_20093499","title":"Arhgef1 regulates alpha5beta1 integrin-mediated matrix metalloproteinase expression and is required for homeostatic lung immunity.","date":"2010","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20093499","citation_count":15,"is_preprint":false},{"pmid":"17463415","id":"PMC_17463415","title":"Arhgef1 is required by T cells for the development of airway hyperreactivity and inflammation.","date":"2007","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17463415","citation_count":15,"is_preprint":false},{"pmid":"22086927","id":"PMC_22086927","title":"Thromboxane receptor signaling is required for fibronectin-induced matrix metalloproteinase 9 production by human and murine macrophages and is attenuated by the Arhgef1 molecule.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22086927","citation_count":15,"is_preprint":false},{"pmid":"12681510","id":"PMC_12681510","title":"Mutation of an N-terminal acidic-rich region of p115-RhoGEF dissociates alpha13 binding and alpha13-promoted plasma membrane recruitment.","date":"2003","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12681510","citation_count":12,"is_preprint":false},{"pmid":"27923664","id":"PMC_27923664","title":"Arhgef1 is expressed in cortical neural progenitor cells and regulates neurite outgrowth of newly differentiated neurons.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27923664","citation_count":11,"is_preprint":false},{"pmid":"32390803","id":"PMC_32390803","title":"CX3CL1 Induces Vertebral Microvascular Barrier Dysfunction via the Src/P115-RhoGEF/ROCK Signaling Pathway.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32390803","citation_count":9,"is_preprint":false},{"pmid":"35037717","id":"PMC_35037717","title":"Integrative multiomics and in silico analysis revealed the role of ARHGEF1 and its screened antagonist in mild and severe COVID-19 patients.","date":"2022","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35037717","citation_count":9,"is_preprint":false},{"pmid":"38823764","id":"PMC_38823764","title":"Apigenin inhibits tumor angiogenesis by hindering microvesicle biogenesis via ARHGEF1.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38823764","citation_count":7,"is_preprint":false},{"pmid":"30994039","id":"PMC_30994039","title":"Arhgef1 Plays a Vital Role in Platelet Function and Thrombogenesis.","date":"2019","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/30994039","citation_count":4,"is_preprint":false},{"pmid":"36434027","id":"PMC_36434027","title":"Interaction kinetics between p115-RhoGEF and Gα13 are determined by unique molecular interactions affecting agonist sensitivity.","date":"2022","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/36434027","citation_count":2,"is_preprint":false},{"pmid":"34109211","id":"PMC_34109211","title":"Structural Design and Analysis of the RHOA-ARHGEF1 Binding Mode: Challenges and Applications for Protein-Protein Interface Prediction.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34109211","citation_count":2,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.26.656196","title":"VerteBrain reveals novel neural and non-neural protein assemblies conserved across vertebrate evolution","date":"2025-05-28","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.26.656196","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.02.25326852","title":"Genetic Heterogeneity and Homogeneity Among Orofacial Cleft Subtypes: Genome-Wide Association Studies in the Cleft Collective","date":"2025-05-03","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.02.25326852","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18890,"output_tokens":6126,"usd":0.07428},"stage2":{"model":"claude-opus-4-6","input_tokens":9817,"output_tokens":3222,"usd":0.194453},"total_usd":0.268733,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"p115 RhoGEF (ARHGEF1) has GTPase-activating protein (GAP) activity specifically toward Gα12 and Gα13, but not Gs, Gi, or Gq subfamily members, mediated through its N-terminal RGS-like domain.\",\n      \"method\": \"Recombinant protein in vitro GTPase activity assay; fusion protein containing the N-terminus of p115\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro biochemical reconstitution with recombinant proteins, foundational paper with 727 citations\",\n      \"pmids\": [\"9641915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Activated Gα13 binds tightly to p115 RhoGEF (ARHGEF1) and directly stimulates its guanine nucleotide exchange activity on RhoA; in contrast, activated Gα12 inhibits this Gα13-mediated stimulation.\",\n      \"method\": \"Recombinant protein binding assay; in vitro GEF activity assay with purified components\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with purified proteins, 665 citations, replicated by companion paper\",\n      \"pmids\": [\"9641916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The pleckstrin homology (PH) domain and a linker region between the RGS and DH domains regulate p115 RhoGEF activity: removal of the PH domain reduces in vitro exchange activity, deletion of the C-terminal 150 amino acids enhances in vivo activity over 5-fold, and endogenous p115 RhoGEF translocates from cytosol to membranes upon LPA or sphingosine 1-phosphate stimulation.\",\n      \"method\": \"Domain deletion mutants; in vitro GEF activity assay; immunoprecipitation of endogenous protein from stimulated cells; subcellular fractionation\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple domain deletion constructs with in vitro and in vivo functional readouts, strong mechanistic detail\",\n      \"pmids\": [\"11384980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Activated Gα13 induces redistribution of p115 RhoGEF from the cytoplasm to plasma membranes; non-palmitoylated Gα13 mutants co-immunoprecipitate with p115 RhoGEF but fail to cause its translocation to the plasma membrane, indicating palmitoylation of Gα13 is required for p115 RhoGEF membrane recruitment but not the physical interaction.\",\n      \"method\": \"Co-immunoprecipitation; fluorescence microscopy of transfected cells; palmitoylation-deficient mutants\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP with mutagenesis, clear functional dissociation of binding vs. translocation\",\n      \"pmids\": [\"10747909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The N-terminal acidic-rich region of p115 RhoGEF, specifically glutamic acids 27 and 29, is required for binding to activated Gα13; however, Gα13-interacting-deficient mutants retain Gα13-dependent plasma membrane recruitment, dissociating binding from translocation.\",\n      \"method\": \"Cell-based co-immunoprecipitation; site-directed mutagenesis; subcellular localization assay\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mutagenesis with functional dissection in cell-based assays, single lab\",\n      \"pmids\": [\"12681510\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Constitutively active Gα12 and Gα13 mutants induce redistribution of p115 RhoGEF (EGFP-tagged) from cytosol to plasma membrane; activation of G12/13-coupled GPCRs causes rapid and reversible translocation of p115 RhoGEF to the plasma membrane.\",\n      \"method\": \"Live-cell fluorescence imaging of EGFP-tagged p115 RhoGEF; pharmacological GPCR activation and antagonism\",\n      \"journal\": \"Journal of Cellular Biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live-cell imaging with constitutively active and pharmacological tools, single lab\",\n      \"pmids\": [\"18320579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Rho activity is required for Gα13-induced, but not Gα12-induced, plasma membrane translocation of p115 RhoGEF; a constitutively PM-localized mutant of p115 RhoGEF shows greatly enhanced Rho-dependent neurite retraction compared to wild-type, demonstrating that PM localization activates p115 RhoGEF signaling.\",\n      \"method\": \"Rho inhibition (C3 transferase); PM-localized mutant expression; neurite retraction assay in PC12 cells; RGS domain mutant analysis\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple mutants and functional assay, single lab\",\n      \"pmids\": [\"19249348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p115 RhoGEF is targeted by microtubules in neighboring epithelial cells to basolateral surfaces during apoptotic cell extrusion; this targeting activates local actin/myosin contraction at the basolateral surface and determines the direction (apical vs. basal) of cell extrusion.\",\n      \"method\": \"Live-cell imaging; microtubule perturbation; localization of p115 RhoGEF by fluorescence microscopy; inhibition of myosin\",\n      \"journal\": \"Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct imaging with microtubule manipulation, clear functional consequence, 113 citations\",\n      \"pmids\": [\"19720875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Angiotensin II activates Arhgef1 in arterial smooth muscle cells through JAK2-mediated phosphorylation of Tyr738 of Arhgef1, which in turn activates RhoA signaling; smooth-muscle-specific Arhgef1 inactivation in mice confers resistance to angiotensin II-dependent hypertension.\",\n      \"method\": \"Kinase inhibition; phosphorylation site mutagenesis (Tyr738); smooth muscle-specific knockout mice; blood pressure measurement; RhoA activity assay\",\n      \"journal\": \"Nature Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — PTM identification with mutagenesis + genetic KO with defined in vivo phenotype, 204 citations\",\n      \"pmids\": [\"20098430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Lsc/p115 RhoGEF (ARHGEF1) and LARG are activated downstream of fibronectin adhesion (but not other matrix proteins), and their combined knockdown significantly reduces RhoA activation and formation of stress fibers and focal adhesions; a catalytically inactive Lsc mutant inhibits RhoA activity and cytoskeletal structures on fibronectin.\",\n      \"method\": \"Affinity pulldown assay for active GEFs; siRNA knockdown; catalytically inactive mutant overexpression; RhoA activity assay; immunofluorescence\",\n      \"journal\": \"Journal of Cell Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (pulldown, siRNA, dominant-negative), 92 citations\",\n      \"pmids\": [\"17971419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The cytoplasmic leucine-zipper region of HIV-1 gp41 interacts with the C-terminal regulatory domain of p115 RhoGEF and inhibits p115-mediated actin stress fiber formation and SRF activation; loss of this interaction impairs HIV-1 replication in human T cells.\",\n      \"method\": \"Co-immunoprecipitation; functional assays (stress fiber formation, SRF reporter); mutagenesis of gp41; viral replication assay\",\n      \"journal\": \"Current Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional assays and mutagenesis, single lab\",\n      \"pmids\": [\"10556093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The linker region connecting the RGS-homology domain and DH domain of p115 RhoGEF acts as an autoinhibitory element (GEF switch); crystal structures of DH/PH alone vs. DH/PH with linker region reveal that the linker disorders the N-terminal extension of the DH domain required for GEF activity.\",\n      \"method\": \"X-ray crystallography; SAXS; in vitro GEF activity assay of deletion constructs\",\n      \"journal\": \"Protein Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus SAXS and biochemical activity assays, multiple orthogonal methods\",\n      \"pmids\": [\"21064165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Activation of p115 RhoGEF by Gα13 requires direct association of Gα13 with the DH domain at a site distinct from the RhoA-binding face; the helical domain of Gα13 docks onto the DH domain, and mutation of Trp in the α3b helix of DH reduces Gα13 binding and ablates stimulation; the RH domain facilitates this DH-domain interaction.\",\n      \"method\": \"SAXS; biochemical binding assays; site-directed mutagenesis of DH domain and Gα13 helical domain; in vitro GEF activity assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural (SAXS) plus mutagenesis and in vitro activity assays, multiple orthogonal approaches\",\n      \"pmids\": [\"22661716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Tension on JAM-A activates RhoA via p115 RhoGEF (and GEF-H1) in a pathway dependent on PI3K, Src family kinases, and FAK; phosphorylation of JAM-A at Ser-284 is required for RhoA activation in response to tension.\",\n      \"method\": \"Pharmacological inhibition; siRNA knockdown; phospho-site mutagenesis; RhoA activity assay; cell stiffness measurement\",\n      \"journal\": \"Molecular Biology of the Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitors and mutagenesis, functional phenotype, single lab\",\n      \"pmids\": [\"26985018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"FAK/p66Shc complex specifically binds and activates p115 RhoGEF and GEF-H1 in response to mechanical tension on fibronectin, leading to RhoA activation; this complex is required for YAP/TAZ nuclear translocation, proliferation on firm substrates, and anoikis in suspension.\",\n      \"method\": \"Pulldown/co-IP; domain mapping (PTB domain, FERM domain); siRNA knockdown; RhoA activity assay; YAP/TAZ localization\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding domain mapping and functional knockdown, single lab\",\n      \"pmids\": [\"27573018\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GPCR-induced and hypoxia-induced ROS activate Src-family kinases, which then activate RhoA via ARHGEF1 in pulmonary artery smooth muscle; subcellular translocation of RhoA and ARHGEF1 is triggered by ROS and blocked by antioxidants, PP2, or ARHGEF1 siRNA; ARHGEF1 co-immunoprecipitates with c-Src in a ROS-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation; siRNA knockdown; live-cell imaging of ARHGEF1 translocation; pharmacological inhibitors; RhoA activity assay\",\n      \"journal\": \"Free Radical Biology and Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus siRNA and live imaging, single lab\",\n      \"pmids\": [\"28673614\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"MCP1 induces tyrosine phosphorylation of p115 RhoGEF (but not PDZ-RhoGEF or LARG) in vascular smooth muscle cells via CCR2-Gi/o-Fyn signaling, leading to Rac1 (not only RhoA) activation and subsequent HASMC migration and proliferation through a Rac1-NFATc1-cyclin D1-CDK6-PKN1-CDK4-PAK1 axis.\",\n      \"method\": \"siRNA knockdown; tyrosine phosphorylation analysis; Rac1 activity assay; migration and proliferation assays; in vivo balloon injury model with siRNA\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo siRNA with signaling pathway analysis, single lab\",\n      \"pmids\": [\"28655771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TGF-β enhances ARHGEF1 protein expression in airway smooth muscle cells; ARHGEF1 siRNA suppresses TGF-β-enhanced BK-induced RhoA translocation, Rho-kinase activity, and contraction; ARHGEF1 mediates TGF-β effects on airway hyperresponsiveness independently of SrcFK and total RhoA-GTP content.\",\n      \"method\": \"siRNA knockdown; live-cell imaging of ARHGEF1/RhoA translocation; MYPT1/MLC20 phosphorylation; isolated bronchiole contraction assay\",\n      \"journal\": \"Journal of Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA with multiple functional readouts including in vitro tissue contraction, single lab\",\n      \"pmids\": [\"29071730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Loss-of-function mutations in ARHGEF1 in humans result in low RhoA activity and low actin polymerization in T and B lymphocytes; ARHGEF1-deficient lymphocytes fail to restrain AKT phosphorylation downstream of ROCK, and enforced ARHGEF1 expression or RhoA activation corrects impaired actin polymerization and AKT regulation.\",\n      \"method\": \"Whole-exome sequencing; RhoA activity assay; actin polymerization assay; AKT phosphorylation assay; rescue by ARHGEF1 re-expression or pharmacological RhoA activation\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human loss-of-function with multiple molecular readouts and rescue experiments\",\n      \"pmids\": [\"30521495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Arhgef1 is essential for Ang II-induced integrin activation in leukocytes; deletion of Arhgef1 prevents Ang II-induced leukocyte recruitment to the endothelium; bone marrow reconstitution experiments establish that Arhgef1 in leukocytes (not stromal cells) is causal in atherosclerosis development.\",\n      \"method\": \"Genetic knockout mice; bone marrow reconstitution; leukocyte adhesion assay; integrin activation assay; atherosclerosis model (high-fat diet, LDLR-/- background)\",\n      \"journal\": \"Journal of Clinical Investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via BM reconstitution with clear cellular mechanism, strong evidence\",\n      \"pmids\": [\"29130930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARHGEF1 and SOS1 and DOCK2 mediate CXCL12-induced LFA-1 activation in T lymphocytes downstream of JAK kinases; ARHGEF1 is tyrosine phosphorylated upon CXCL12 stimulation in a JAK- and pertussis toxin-sensitive manner, and its knockdown impairs RhoA and Rac1 activation and LFA-1-mediated rapid adhesion.\",\n      \"method\": \"siRNA knockdown; LFA-1 affinity assay; adhesion assay under flow; RhoA/Rac1 activity assay; tyrosine phosphorylation analysis; JAK and pertussis toxin inhibitors\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays with siRNA and pharmacological tools, single lab\",\n      \"pmids\": [\"27986909\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Arhgef1 deficiency in platelets impairs RhoA-ROCK axis activation, leading to defective aggregation, granule secretion, αIIbβ3 integrin activation, clot retraction, and spreading, as well as prolonged bleeding times and impaired thrombosis in vivo.\",\n      \"method\": \"Genetic knockout mice; platelet aggregation assay; granule secretion assay; integrin activation assay; clot retraction; carotid artery occlusion model; tail bleeding time\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo platelet function assays in KO mice, single lab\",\n      \"pmids\": [\"30994039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Arhgef1 negatively regulates neurite outgrowth by activating RhoA while inhibiting Rac1 and Cdc42; Arhgef1 promotes F-actin polymerization in neurons, likely through inhibiting cofilin activity; pharmacological RhoA blockade rescues excess neurite growth caused by Arhgef1 overexpression.\",\n      \"method\": \"siRNA knockdown; overexpression in Neuro-2a cells and primary cortical neurons; RhoA/Rac1/Cdc42 activity assays; cofilin phosphorylation analysis; actin staining; neurite length measurement\",\n      \"journal\": \"FEBS Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — gain- and loss-of-function with GTPase activity assays and downstream effector analysis, single lab\",\n      \"pmids\": [\"27489999\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"p115 RhoGEF interacts with Gα13 for a significantly shorter duration than LARG or PDZ-RhoGEF, determined by a single amino acid in the rgRGS domain; mutation of this residue increases interaction time with Gα13, enhances agonist sensitivity, and increases GAP activity toward Gα13 in intact cells.\",\n      \"method\": \"FRET-based single-cell interaction kinetics assay; site-directed mutagenesis; in vitro GAP activity assay\",\n      \"journal\": \"Communications Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — FRET kinetics with mutagenesis, in vitro GAP assay, single lab\",\n      \"pmids\": [\"36434027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Apigenin targets ARHGEF1 to inhibit Cdc42 activity, thereby blocking microvesicle biogenesis from tumor cells and reducing VEGF90K-mediated tumor angiogenesis.\",\n      \"method\": \"siRNA knockdown; Cdc42 activity assay; microvesicle secretion assay; pharmacological treatment with apigenin; VEGF transport assay\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional knockdown with mechanistic pathway dissection, single lab\",\n      \"pmids\": [\"38823764\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Arhgef1 regulates α5β1 integrin-mediated matrix metalloproteinase (MMP) expression in macrophages; Arhgef1-deficient macrophages show increased MMP expression and activity when cultured on fibronectin in an α5β1-dependent manner.\",\n      \"method\": \"Genetic knockout mice; macrophage culture on fibronectin; MMP activity assay; integrin blocking antibodies; in vivo leukocyte transfer\",\n      \"journal\": \"American Journal of Pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO macrophages with integrin-specific blocking and in vivo transfer, single lab\",\n      \"pmids\": [\"20093499\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARHGEF1 (p115 RhoGEF) is a RGS domain-containing guanine nucleotide exchange factor that directly links Gα12/13 heterotrimeric G protein signaling to RhoA activation: its RGS domain acts as a GAP for Gα12/13 while activated Gα13 docks onto both the RH and DH domains to relieve autoinhibition imposed by a linker region and stimulate RhoA exchange activity; the protein is also tyrosine-phosphorylated (e.g., Tyr738 by JAK2 downstream of angiotensin II, or by Src-family kinases and Fyn downstream of chemokine/ROS signaling) to activate RhoA and Rac1 in vascular smooth muscle, leukocytes, platelets, and neurons, with Gα13-driven plasma membrane translocation constituting an additional activation mechanism; these activities regulate cytoskeletal dynamics, cell migration and adhesion, apoptotic cell extrusion, neurite outgrowth, and vascular tone.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ARHGEF1 (p115 RhoGEF) is a Gα12/13-regulated guanine nucleotide exchange factor for RhoA that couples heterotrimeric G protein signaling to cytoskeletal remodeling, cell adhesion, vascular tone, immune cell trafficking, and apoptotic cell extrusion. Its N-terminal RGS domain functions as a GTPase-activating protein selective for Gα12 and Gα13 [PMID:9641915], while activated Gα13 binds the DH domain at a site distinct from the RhoA-binding surface to relieve autoinhibition imposed by an interdomain linker, as revealed by crystallography and SAXS [PMID:21064165, PMID:22661716]; Gα13-driven palmitoylation-dependent translocation to the plasma membrane further potentiates signaling [PMID:10747909, PMID:18320579]. Tyrosine phosphorylation by JAK2 (Tyr738, downstream of angiotensin II) or Src-family kinases activates ARHGEF1-dependent RhoA and Rac1 signaling in vascular smooth muscle, leukocytes, and platelets, and smooth-muscle-specific knockout confers resistance to angiotensin II-induced hypertension [PMID:20098430, PMID:27986909, PMID:29130930]. Loss-of-function mutations in human ARHGEF1 cause impaired RhoA-mediated actin polymerization and dysregulated AKT signaling in lymphocytes, resulting in primary immunodeficiency [PMID:30521495].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Establishing that p115 RhoGEF is both a GAP for Gα12/13 and the effector through which Gα13 directly stimulates RhoA exchange activity resolved the long-standing question of how G12/13-coupled receptors activate Rho GTPases.\",\n      \"evidence\": \"In vitro reconstitution with recombinant proteins measuring GTPase acceleration and nucleotide exchange\",\n      \"pmids\": [\"9641915\", \"9641916\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of simultaneous GAP and GEF activities not yet resolved\", \"Relative contributions of Gα12 vs. Gα13 to physiological signaling unclear\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Demonstration that Gα13 drives plasma membrane translocation of p115 RhoGEF in a palmitoylation-dependent manner established membrane recruitment as a key activation mechanism, separable from the physical Gα13–p115 interaction.\",\n      \"evidence\": \"Co-immunoprecipitation and fluorescence microscopy with palmitoylation-deficient Gα13 mutants in transfected cells\",\n      \"pmids\": [\"10747909\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the membrane-targeting determinant on p115 RhoGEF itself unknown\", \"Whether endogenous receptors use the same translocation mechanism not shown\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Mapping of intramolecular regulatory elements showed that the PH domain supports catalytic activity while the C-terminal region autoinhibits it, and that endogenous p115 RhoGEF translocates upon GPCR ligand stimulation, linking domain architecture to signal-dependent activation.\",\n      \"evidence\": \"Domain deletion mutants with in vitro GEF assays; subcellular fractionation of endogenous protein after LPA/S1P stimulation\",\n      \"pmids\": [\"11384980\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic mechanism of autoinhibition not resolved at this stage\", \"Role of the C-terminal region as a protein–protein interaction platform only partially explored\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identification of ARHGEF1 (together with LARG) as fibronectin-specific integrin-activated RhoGEFs placed the protein in the adhesion-to-cytoskeleton signaling axis beyond GPCR pathways.\",\n      \"evidence\": \"Affinity pulldown for active GEFs, siRNA knockdown, and dominant-negative mutant in cells on fibronectin\",\n      \"pmids\": [\"17971419\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct integrin–ARHGEF1 binding not demonstrated\", \"Upstream kinases linking integrin engagement to ARHGEF1 activation not identified\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that neighboring epithelial cells target p115 RhoGEF to the basolateral surface via microtubules during apoptotic extrusion revealed a non-GPCR, cytoskeleton-directed mechanism of spatial activation with direct morphogenetic consequence.\",\n      \"evidence\": \"Live-cell imaging with microtubule perturbation and myosin inhibition in epithelial monolayers\",\n      \"pmids\": [\"19720875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular link between microtubule plus-ends and p115 RhoGEF targeting unknown\", \"Whether this mechanism operates in vivo tumor cell extrusion untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of JAK2-mediated Tyr738 phosphorylation as the angiotensin II–induced activation switch, coupled with the hypertension-resistant phenotype of smooth-muscle-specific Arhgef1 knockout mice, established ARHGEF1 as a central mediator of vascular tone.\",\n      \"evidence\": \"Phospho-site mutagenesis, kinase inhibition, conditional knockout mice, and blood pressure measurement\",\n      \"pmids\": [\"20098430\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other tyrosine sites contribute to activation in vascular smooth muscle not resolved\", \"Downstream effectors beyond ROCK not fully mapped in vivo\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Crystal structures of the DH/PH cassette with and without the linker region revealed that the linker disorders the N-terminal DH extension required for catalysis, defining the structural basis of autoinhibition (the 'GEF switch').\",\n      \"evidence\": \"X-ray crystallography and SAXS combined with in vitro GEF activity assays of truncation constructs\",\n      \"pmids\": [\"21064165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Gα13 binding relieves this autoinhibition structurally not captured in a single complex structure\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Mapping the Gα13–DH domain interface to the α3b helix showed that Gα13 contacts a surface distinct from the RhoA-binding face, with the RH domain facilitating this interaction, explaining how Gα13 allosterically stimulates exchange activity.\",\n      \"evidence\": \"SAXS, site-directed mutagenesis of DH and Gα13 helical domains, and in vitro GEF assays\",\n      \"pmids\": [\"22661716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full atomic-resolution structure of the ternary Gα13–p115–RhoA complex lacking\", \"Whether linker displacement and DH-domain contact are sequential or concerted not determined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Parallel studies in T lymphocytes and mechanotransduction showed ARHGEF1 is tyrosine-phosphorylated downstream of JAK/Src-family kinases upon chemokine or mechanical stimulation to activate both RhoA and Rac1, broadening its effector spectrum beyond RhoA alone and linking it to integrin inside-out signaling and YAP/TAZ mechanosensing.\",\n      \"evidence\": \"siRNA knockdown, LFA-1 affinity/adhesion assays, phosphorylation analysis, RhoA/Rac1 pulldowns, YAP/TAZ localization\",\n      \"pmids\": [\"27986909\", \"27489999\", \"27573018\", \"26985018\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct phosphorylation by Src-family kinases at specific residues not mapped\", \"Whether Rac1 activation is direct or via an intermediate pathway unresolved\", \"Relative contribution of ARHGEF1 vs. GEF-H1 in mechanotransduction not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"In vivo studies using Arhgef1-knockout mice with bone marrow reconstitution demonstrated that leukocyte-intrinsic Arhgef1 is required for angiotensin II–induced integrin activation, endothelial adhesion, and atherosclerosis development, establishing a cell-autonomous immune function.\",\n      \"evidence\": \"Bone marrow chimera in LDLR−/− mice, leukocyte adhesion assay, integrin activation assay\",\n      \"pmids\": [\"29130930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific Gα subunit upstream of Arhgef1 in leukocytes not identified\", \"Whether the vascular and immune roles synergize in atherogenesis not dissected\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Human loss-of-function mutations in ARHGEF1 were shown to cause defective RhoA-dependent actin polymerization and ROCK-mediated AKT restraint in lymphocytes, rescued by ARHGEF1 re-expression, establishing ARHGEF1 deficiency as a cause of primary immunodeficiency.\",\n      \"evidence\": \"Whole-exome sequencing, RhoA/actin/AKT assays in patient lymphocytes, rescue by ARHGEF1 expression or pharmacological RhoA activation\",\n      \"pmids\": [\"30521495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full clinical spectrum of ARHGEF1 deficiency in additional kindreds not defined\", \"Whether the AKT dysregulation drives lymphomagenesis not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"FRET-based kinetic analysis revealed that p115 RhoGEF has a much shorter interaction time with Gα13 than LARG or PDZ-RhoGEF, determined by a single rgRGS-domain residue, suggesting that differential kinetics tune signaling output among the three RH-RhoGEFs.\",\n      \"evidence\": \"Single-cell FRET kinetics, site-directed mutagenesis, and in vitro GAP assay\",\n      \"pmids\": [\"36434027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological consequence of altered interaction kinetics not demonstrated in native tissue\", \"Whether kinetic differences translate to distinct downstream signaling dynamics unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the full-length Gα13–p115 RhoGEF–RhoA ternary complex and the precise mechanism by which tyrosine phosphorylation at Tyr738 allosterically activates GEF activity remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ternary complex structure available\", \"Structural basis of phospho-Tyr738-mediated activation unknown\", \"In vivo redundancy among RH-RhoGEFs not systematically addressed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 23]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 11, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3, 5]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 8, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18, 19, 20]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNA13\",\n      \"GNA12\",\n      \"RHOA\",\n      \"JAK2\",\n      \"SRC\",\n      \"FYN\",\n      \"FAK\",\n      \"LARG\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}